Death or abnormal neurodevelopmental outcome (various definitions) · preterm infants at risk for bronchopulmonary dysplasia
Later showed no clear difference in death or abnormal neurodevelopmental outcome (various definitions) compared with earlier initiation of dexamethasone therapy (low certainty).
1 finding from 1 review
Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants at risk for bronchopulmonary dysplasia
Pulse may leads to higher death or bronchopulmonary dysplasia at 36 weeks' PMA compared with continuous dexamethasone therapy (low certainty).
1 finding from 1 review
Death or abnormal neurodevelopmental outcome (various definitions) · preterm infants at risk for bronchopulmonary dysplasia
It is very uncertain whether pulse changes death or abnormal neurodevelopmental outcome (various definitions) compared with continuous dexamethasone therapy (very low certainty).
1 finding from 1 review
Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants at risk for bronchopulmonary dysplasia
Individual tailored showed no clear difference in death or bronchopulmonary dysplasia at 36 weeks PMA compared with continuous tapered dexamethasone regimen (low certainty).
1 finding from 1 review
UGIH‐related mortality · people with acute UGIH
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
SAEs · people with acute UGIH
1 finding from 1 review
All‐cause mortality · people with acute UGIH
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Visualisation of gastric mucosa · people with acute UGIH
It is very uncertain whether erythromycin plus nasogastric tube lavage changes visualisation of gastric mucosa compared with metoclopramide plus nasogastric tube lavage (very low certainty).
1 finding from 1 review
NSAEs · people with acute UGIH
1 finding from 1 review
Rebleeding · people with acute UGIH
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Blood transfusion · people with acute UGIH
1 finding from 1 review
4a.Death at any time during initial hospitalization – doxapram compared to no treatment for the treatment of apnea · treatment of apnea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
5a. Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram compared to no treatment for the treatment of apnea · treatment of apnea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
5b. Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram compared to alternative treatment for the treatment of apnea · treatment of apnea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
1a.'Clinical apnea' after initiation of treatment – doxapram compared to no treatment for the prevention of reintubation · prevention of reintubation
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
2a. Failed apnea reduction after 2–7 days – doxapram compared to no treatment for the prevention of reintubation · prevention of reintubation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
2b. Failed apnea reduction after 2–7 days – doxapram compared to alternative treatment for the prevention of reintubation · prevention of reintubation
It is very uncertain whether doxapram changes 2b. Failed apnea reduction after 2–7 days – doxapram compared to… compared with no treatment, placebo, methylxanthine (including theophylline,… (very low certainty).
1 finding from 1 review
3a. Chronic lung disease at 36 weeks' postmenstrual age – doxapram compared to no treatment for the prevention of reintubation · prevention of reintubation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
4a. Death (at any time during initial hospitalization) – doxapram compared to no treatment for the prevention of reintubation · prevention of reintubation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
4b. Death (at any time during initial hospitalization) – doxapram compared to alternative treatment for the prevention of reintubation · prevention of reintubation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found